Issued Patents All Time
Showing 1–14 of 14 patents
| Patent # | Title | Co-Inventors | Date |
|---|---|---|---|
| 12264198 | Tandem diabody for CD16A-directed NK-cell engagement | Thorsten Ross, Ivica Fucek, Kristina Ellwanger, Michael Weichel, Uwe Reusch +2 more | 2025-04-01 |
| 12076384 | Bispecific EGFR/CD16 antigen-binding protein | Michael Kluge, Michael Tesar, Ivica Fucek, Kristina Ellwanger, Uwe Reusch +2 more | 2024-09-03 |
| 11572415 | Multivalent FV antibodies | Kristina Ellwanger, Ivica Fucek, Thorsten Ross, Thomas Mueller, Erich Rajkovic +2 more | 2023-02-07 |
| 11535672 | Combination of an anti-CD16A antibody with a cytokine | Joachim Koch, Jens Pahl, Uwe Reusch, Thorsten Ross, Erich Rajkovic +1 more | 2022-12-27 |
| 11510972 | Bispecific EGFR/CD16 antigen-binding protein | Michael Kluge, Michael Tesar, Ivica Fucek, Kristina Ellwanger, Uwe Reusch +2 more | 2022-11-29 |
| 11267900 | Antibodies directed to HER-3 and uses thereof | Mike Rothe, Eric Borges, Larry Green, Susanne Hartmann | 2022-03-08 |
| 11180558 | Tandem diabody for CD16A-directed NK-cell engagement | Thorsten Ross, Ivica Fucek, Kristina Ellwanger, Michael Weichel, Uwe Reusch +2 more | 2021-11-23 |
| 11167029 | Combination of a CD30XCD16 antibody with a PD-1 antagonist for therapy | Uwe Reusch, Jens-Peter Marschner, Stefan Knackmuss | 2021-11-09 |
| 11001633 | NK cell engaging antibody fusion constructs | Michael Tesar, Kristina Ellwanger, Ivica Fucek, Uwe Reusch, Thorsten Ross +2 more | 2021-05-11 |
| 10365283 | Activated HER3 as a marker for predicting therapeutic efficacy | Mike Rothe | 2019-07-30 |
| 10100124 | Antibodies directed to HER-3 and uses thereof | Mike Rothe, Eric Borges, Susanne Hartmann, Larry Green | 2018-10-16 |
| 9249230 | Antibodies directed to HER-3 and uses thereof | Mike Rothe, Eric Borges, Susanne Hartmann, Larry Green | 2016-02-02 |
| 8771695 | Antibodies directed to HER-3 and uses thereof | Mike Rothe, Susanne Hartmann, Daniel J. Freeman, Robert Radinsky, Eric Borges | 2014-07-08 |
| 7705130 | Antibodies directed to HER-3 and uses thereof | Mike Rothe, Susanne Hartmann, Eric Borges, Larry Green | 2010-04-27 |